JSC Grindeks informs that the company has received a certification of Saudi Food and Drug Authority certifying the compliance of Grindeks final dosage forms –tablets and capsules – with the Saudi Arabia’s medicines manufacturing requirements.
The supervising institution of medicinal products in Saudi Arabia issued the certificate after a successful multi-step inspection of JSC Grindeks final dosage forms manufacturing site at Krustpils Street 53, Riga.
JSC Grindeks Chairman of the Board Juris Bundulis: “The positive assessment of the compliance of Grindeks final dosage forms manufacturing site with the Saudi Arabia’s pharmaceutical manufacturing standard opens us new export opportunities to the Middle East region. The Saudi Food and Drug Authority is very demanding and rigorous, which is why its certification is highly valued in other Gulf countries.”
In recent years, JSC Grindeks has been strategically expanding the range of oncological medicines therefore medicines of this therapeutic group will be the first with which JSC Grindeks plans to enter the Saudi Arabia’s market.
At the same time, the Saudi Food and Drug Authority is organizing an inspection at “HBM Pharma” in Slovakia, a subsidiary of JSC Grindeks, to evaluate the compliance of injections solutions with Saudi Arabia’s medicines manufacturing requirements.
